Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
There is significant commercial potential on offer for the leading CAR-NK developers. While companies committed to continued CAR-T development will need to adapt and innovate in order to remain relevant, especially considering this disruptive new drug class.
Latest From Innovation
An early childhood fascination with the natural world led Cesar de la Fuente into the fields of microbiology and immunology. A PhD from the University of British Columbia – and postdoc work at Massachusetts Institute of Technology – helped him combine computer science principles with biological processes. As the leader of a machine biology group and lab at the University of Pennsylvania, de la Fuente is working to develop new antibiotics to treat deadly bacterial infections.
Investigational uses of psilocybin and MDMA – two illicit drugs associated with recreational use and abuse in the US – will soon enter the later stages of clinical development for the treatment of CNS disorders including depression, addiction and post-traumatic stress disorder. Janssen’s experiences marketing Spravato, an inhaled form of ketamine indicated for severe forms of depression, may be instructive for companies working to bring other psychoactive compounds into mainstream use as therapeutics.
Real-time decision support came of age in dramatic style during COVID-19. GE Healthcare’s CEO of Clinical Command Centers Jeff Terry explains that AI- and app-based health system collaboration and virtualized care will become increasingly embedded as health care delivery transforms.
CMS patent attorneys Jane Hollywood and Rob Stephen say COVID-19 has not dented the enthusiasm of medtech start-up entrepreneurs from pushing back the technology boundaries in patient care delivery – in fact, they are getting younger.
A two and half year-old partnership between Adaptive Biotechnologies and Microsoft that began with a focus on Lyme disease has transitioned to mapping immune responses to the SARS-CoV-2 virus. By identifying and matching T cell receptors to antigens associated with the virus – and leveraging the power of machine learning – the companies hope to improve COVID-19 vaccine development, locate potential antibodies for drug development and create better, more sensitive diagnostics.
The total addressable market for genomics infectious disease testing is increasing, says Illumina, after becoming the first company to receive a US EUA for a next generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego group.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.